Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Processa Pharmaceuticals, Inc. Common (PCSA)

Pharmaceutical Preparations

https://www.processapharmaceuticals.com

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100.

7380 COCA COLA DRIVE, SUITE 106
HANOVER, MD

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/07/2013

Market Cap

4,624,203

Shares Outstanding

24,630,000

Weighted SO

1,231,573

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

ACOGF --.--%

EPRXF --.--%

ACXP --.--%

FENC --.--%

CMRA --.--%

SABS --.--%

FRTX --.--%

THRD --.--%

ELYM --.--%

Beta

0.5960

Last Div

0.0000

Range

1.3-18.0

Chg

0.1098

Avg Vol

1054950

Mkt Cap

4624203

Exch

NASDAQ

Country

US

Phone

443 776 3133

DCF Diff

1.0827

DCF

0.3473

Div Yield

0.0000

P/S

0.0000

EV Multiple

0.0621

P/FV

0.7032

Div Yield %

0.0000

P/E

-0.4143

PEG

-0.0055

Payout

0.0000

Current Ratio

4.8193

Quick Ratio

4.8193

Cash Ratio

3.5904

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

69.8899

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.4117

ROA

-1.3450

ROE

-1.5110

ROCE

-2.2049

NI/EBT

1.0000

EBT/EBIT

0.7665

EBIT/Rev

0.0000

Debt Ratio

0.0156

D/E

0.0197

LT Debt/Cap

0.0042

Total Debt/Cap

0.0193

Int Coverage

-3.1841

CF/Debt

-78.0914

Equity Multi

1.2619

Rec Turnover

0.0000

Pay Turnover

5.2225

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-3.1105

FCF/Share

-3.1114

Cash/Share

1.8674

OCF/Sales

0.0000

FCF/OCF

1.0003

CF Coverage

-78.0914

ST Coverage

-99.5860

CapEx Coverage

-3342.7666

Div&CapEx Cov

-3342.7666

P/BV

0.7032

P/B

0.7032

P/S

0.0000

P/E

-0.4143

P/FCF

-0.4982

P/OCF

-0.4565

P/CF

-0.4565

PEG

-0.0055

P/S

0.0000

EV Multiple

0.0621

P/FV

0.7032

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 30, 22:17 Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire Inc. Jan 28, 01:30 Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire Inc. Jan 19, 07:45 Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer GlobeNewswire Inc. Jan 18, 07:45 Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split GlobeNewswire Inc. Jan 02, 17:06 Processa Pharmaceuticals to Present at the Biotech Showcase 2024 GlobeNewswire Inc. Nov 13, 13:40 Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Revenue Product Segmentation